197 related articles for article (PubMed ID: 28591272)
1. S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression.
Correia-Melo FS; Silva SS; Araújo-de-Freitas L; Quarantini LC
Braz J Psychiatry; 2017; 39(2):188-189. PubMed ID: 28591272
[No Abstract] [Full Text] [Related]
2. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
[No Abstract] [Full Text] [Related]
3. Esketamine nasal spray (Spravato) for treatment-resistant depression.
Med Lett Drugs Ther; 2019 Apr; 61(1569):54-57. PubMed ID: 31169797
[No Abstract] [Full Text] [Related]
4. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
Włodarczyk A; Cubała WJ
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
[TBL] [Abstract][Full Text] [Related]
5. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
6. Can we confidently use ketamine as a clinical treatment for depression?
Loo C
Lancet Psychiatry; 2018 Jan; 5(1):11-12. PubMed ID: 29277196
[No Abstract] [Full Text] [Related]
7. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G
Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114
[TBL] [Abstract][Full Text] [Related]
8. Ketamine helps a third of patients with treatment resistant depression, finds small UK study.
Torjesen I
BMJ; 2014 Apr; 348():g2576. PubMed ID: 24699320
[No Abstract] [Full Text] [Related]
9. [Ketamine for treatment of acute depression].
Hjerrild S; Bjerre J; Pedersen RH; Videbech P
Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
[TBL] [Abstract][Full Text] [Related]
10. Ketamine as an alternative treatment for treatment-resistant depression.
Dowben JS; Grant JS; Keltner NL
Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
[No Abstract] [Full Text] [Related]
11. Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers.
Mischel NA; Balon R
J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):233-235. PubMed ID: 33905639
[No Abstract] [Full Text] [Related]
12. New use for an old drug: oral ketamine for treatment-resistant depression.
Swiatek KM; Jordan K; Coffman J
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27489070
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
14. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
[No Abstract] [Full Text] [Related]
15. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
Wang JCC; Swainson J
J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
[No Abstract] [Full Text] [Related]
16. Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh DA; Niciu MJ; Ionescu DF; Nolan NM; Richards EM; Brutsche NE; Guevara S; Zarate CA
J Affect Disord; 2014 Apr; 159():56-61. PubMed ID: 24679390
[TBL] [Abstract][Full Text] [Related]
17. Ketamine for the treatment of depression.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
[TBL] [Abstract][Full Text] [Related]
18. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
[TBL] [Abstract][Full Text] [Related]
19. Ketamine-induced affective switch in a patient with treatment-resistant depression.
Banwari G; Desai P; Patidar P
Indian J Pharmacol; 2015; 47(4):454-5. PubMed ID: 26288483
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
Chang L; Zhang K; Pu Y; Qu Y; Wang SM; Xiong Z; Ren Q; Dong C; Fujita Y; Hashimoto K
Pharmacol Biochem Behav; 2019 Jun; 181():53-59. PubMed ID: 31034852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
